Phase II trial of HyperCVAD and Dasatinib in patients with relapsed Philadelphia chromosome positive acute lymphoblastic leukemia or blast phase chronic myeloid leukemia

類似資料

• HyperCVAD plus Imatinib or Dasatinib in Lymphoid Blastic Phase Chronic Myeloid Leukemia
  著者:: Strati, Paolo, 等
  出版事項: (2013)
• First report of phase 2 study of dasatinib with hyper-CVAD for the frontline treatment of patients with Philadelphia chromosome–positive (Ph(+)) acute lymphoblastic leukemia
  著者:: Ravandi, Farhad, 等
  出版事項: (2010)
• Secondary Myelodysplastic Syndrome in a Patient with Philadelphia-Positive Acute Lymphoblastic Leukemia after Achieving a Major Molecular Response with HyperCVAD plus Imatinib Mesylate
  著者:: Vega-Ruiz, Arturo, 等
  出版事項: (2008)
• Long-Term Follow-up of Phase II Study of Chemotherapy Plus Dasatinib for the Initial Treatment of Patients with Philadelphia-Chromosome Positive Acute Lymphoblastic Leukemia
  著者:: Ravandi, Farhad, 等
  出版事項: (2015)
• A Phase I/II Study of the mTOR Inhibitor Everolimus in Combination with HyperCVAD Chemotherapy in Patients with Relapsed / Refractory Acute Lymphoblastic Leukemia
  著者:: Daver, Naval, 等
  出版事項: (2015)